Dr. Aggarwal on the Future of ADT for Patients With Prostate Cancer | OncLive

Dr. Aggarwal on the Future of ADT for Patients With Prostate Cancer

November 1, 2017

Rahul Aggarwal, MD, an assistant professor of Hematology/Oncology, director of the STAND Clinic, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses the future of androgen deprivation therapy (ADT) for patients with prostate cancer.

Rahul Aggarwal, MD, an assistant professor of Hematology/Oncology, director of the STAND Clinic, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses the future of androgen deprivation therapy (ADT) for patients with prostate cancer.

Studies have shown that early application of these potent therapies demonstrates benefit. There is a lot of ongoing drug development for high-risk patients who do not respond well to ADT or whose prostate-specific antigens do not decline fast enough after induction hormone therapy, says Aggarwal.

The impact of the early use of these therapies on the time to progression remains to be seen. The question also arises of how to treat more aggressive cancer for patients who are castration resistant, had their androgen receptor pathway suppressed, or have already been treated with abiraterone acetate (Zytiga), enzalutamide (Xtandi), or apalutamide.


x